The SYK inhibitor used in this study, R406 is the orally active metabolite of fostamatinib, which is currently in clinical trials for autoimmune thrombocytopenia, haemolytic anaemia and IgA nephropathy. The gene discussed is SYK; the disease is autoimmune thrombocytopenia.